LED operating light market is experiencing robust expansion driven by rising procedural volumes, growing adoption of minimally invasive surgery, and...
DURHAM, N.C. and SEOUL, South Korea, Nov. 17, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics...
New deep learning system integrates images and clinical details, improving early skin cancer diagnosis and aiding in smart healthcare INCHEON,...
SAN FRANCISCO, Nov. 17, 2025 /PRNewswire/ -- On July 24, 2025 a life-saving event unfolded when a trained citizen volunteer...
CVAUSA, the largest network of private cardiology groups in the U.S., plans to broadly adopt Flyrcado in line with its...
Presenting INTASYL siRNA Drug TechnologyKing of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is...
Cash expected to fund operations into the second half of 2026Company focused on advancing next-generation anti-cancer therapies derived from well-established...
SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has...
Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure...
SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health...
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in...
OXFORD, England, Nov. 17, 2025 /PRNewswire/ -- Accession Therapeutics Limited, a biopharmaceutical company developing next generation cancer immunotherapies, today announced it...
Company to host investor conference call and webcast on Monday, November 17th, at 9:00am ESTPITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE)...
MIRAMAR, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage...
Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarterNEW HAVEN, Conn., Nov. 14, 2025 (GLOBE NEWSWIRE)...
CAESAREA, Israel, Nov. 14, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that...
Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA...
Continues Execution of Strategic Transformation and Advancement of Biologics Pipeline FREMONT, CA / ACCESS Newswire / November 14, 2025 /...
Click here to registerCompany plans to file its Earnings Report on November 14, 2025 on Form 10-Q for the quarter...
SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...